cmi_logo.png
[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 29, 2023 15:00 ET | Custom Market Insights
Austin, TX, USA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Organ Transplantation Market Size, Trends and Insights By Product Type (Organ...
biosig_rgb.png
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 13, 2023 16:30 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and...
logo.png
Blood Pressure Measuring Devices Estimated USD 3,350 Million Market by 2032
November 09, 2023 11:00 ET | Precedence Research
Ottawa, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The global blood pressure monitoring devices market is projected to surpass around USD 2,380 million by 2029, According to Towards Healthcare. North...
biosig_rgb.png
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 09, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 16:05 ET | Tenaya Therapeutics, Inc.
Commenced Patient Dosing in MyPeak-1TM Phase 1b Trial of TN-201 in MYBPC3-Associated Hypertrophic Cardiomyopathy Presented Positive Phase 1 Data for TN-301 for the Potential Treatment of Heart...
logo.jpg
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 07:00 ET | Lexicon Pharmaceuticals, Inc.
Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community...
biosig_rgb.png
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
November 07, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Westport, CT, November 7, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company...
biosig_rgb.png
BioSig’s New PURE EP™ Subscription Model Adopted by Mayo Clinic-Phoenix for World-Class Cardiac Care
November 02, 2023 08:00 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 02, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company committed to delivering unprecedented accuracy and...
biosig_rgb.png
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
November 01, 2023 08:30 ET | BioSig Technologies, Inc.
Westport, CT, Nov. 01, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and...
Stereotaxis Logo - New Tagline - Black Text.png
Abbott and Stereotaxis Technologies Used in First Integrated Procedures in the United States
October 31, 2023 08:57 ET | Stereotaxis, Inc.
Stereotaxis (NYSE: STXS) & Abbott (NYSE:ABT) announce the first patients in the US have been treated successfully utilizing combined technologies